Immature Platelet Fraction as an Independent Marker of Adverse Outcomes in an Intensive Cardiovascular Care Unit.

IF 5.2 2区 医学 Q1 HEMATOLOGY
Elad Asher, Louay Taha, Mohammad Karmi, Akiva Brin, Pierre Sabouret, Mamas A Mamas, Noam Fink, Ari Naimark, Amjad Abu-Salman, Michael Glikson
{"title":"Immature Platelet Fraction as an Independent Marker of Adverse Outcomes in an Intensive Cardiovascular Care Unit.","authors":"Elad Asher, Louay Taha, Mohammad Karmi, Akiva Brin, Pierre Sabouret, Mamas A Mamas, Noam Fink, Ari Naimark, Amjad Abu-Salman, Michael Glikson","doi":"10.1055/a-2944-1196","DOIUrl":null,"url":null,"abstract":"<p><p>Platelet activation and thrombopoiesis are central to acute cardiovascular disease pathophysiology, yet the prognostic role of the immature platelet fraction (IPF) remains incompletely defined in heterogeneous intensive cardiovascular care unit (ICCU) populations.We conducted a single-center, observational study of 6,725 consecutive ICCU admissions with IPF measured. The primary endpoint was in-hospital all-cause mortality using multivariable logistic regression, and discrimination by receiver operating characteristic analysis.Median age was 70 years; 31.8% were women. Increasing IPF quartiles showed a stepwise rise in mortality (2.1 to 3.7%; p-trend = 0.003), acute renal failure (ARF) (2.4 to 5.1%; <i>p</i> < 0.001), malignant arrhythmia (0.9 to 2.2%; <i>p</i> = 0.002), and in-hospital cardiogenic shock (2.7 to 4.7%; <i>p</i> = 0.008); the regression analysis for cardiogenic shock was restricted to incident cases among non-shock admissions (<i>n</i> = 5,778). After multivariable adjustment, each 1 natural-log-unit increment in IPF (∼1.7× raw IPF) remained independently associated with mortality (OR 1.55, 95% CI: 1.10-2.19), ARF (OR 1.75, 1.37-2.25), malignant arrhythmia (OR 2.07, 1.44-2.98), and cardiogenic shock (OR 1.51, 1.16-1.96). Discrimination of IPF alone was modest (AUC 0.57-0.59), but incorporation into multivariable models improved performance (mortality AUC 0.78). Reclassification analysis demonstrated incremental value beyond baseline (categorical net reclassification improvement [NRI] +6.9 to +12.1%; continuous NRI 0.14-0.28).In this large, contemporary ICCU cohort, elevated IPF was independently associated with in-hospital mortality, as well as adverse outcomes. Although not a standalone discriminator, IPF is a readily available, low-cost biomarker that may enhance early mortality risk stratification when integrated with established clinical variables, supporting further evaluation in multimodal and machine learning-based prediction frameworks.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis and haemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2944-1196","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Platelet activation and thrombopoiesis are central to acute cardiovascular disease pathophysiology, yet the prognostic role of the immature platelet fraction (IPF) remains incompletely defined in heterogeneous intensive cardiovascular care unit (ICCU) populations.We conducted a single-center, observational study of 6,725 consecutive ICCU admissions with IPF measured. The primary endpoint was in-hospital all-cause mortality using multivariable logistic regression, and discrimination by receiver operating characteristic analysis.Median age was 70 years; 31.8% were women. Increasing IPF quartiles showed a stepwise rise in mortality (2.1 to 3.7%; p-trend = 0.003), acute renal failure (ARF) (2.4 to 5.1%; p < 0.001), malignant arrhythmia (0.9 to 2.2%; p = 0.002), and in-hospital cardiogenic shock (2.7 to 4.7%; p = 0.008); the regression analysis for cardiogenic shock was restricted to incident cases among non-shock admissions (n = 5,778). After multivariable adjustment, each 1 natural-log-unit increment in IPF (∼1.7× raw IPF) remained independently associated with mortality (OR 1.55, 95% CI: 1.10-2.19), ARF (OR 1.75, 1.37-2.25), malignant arrhythmia (OR 2.07, 1.44-2.98), and cardiogenic shock (OR 1.51, 1.16-1.96). Discrimination of IPF alone was modest (AUC 0.57-0.59), but incorporation into multivariable models improved performance (mortality AUC 0.78). Reclassification analysis demonstrated incremental value beyond baseline (categorical net reclassification improvement [NRI] +6.9 to +12.1%; continuous NRI 0.14-0.28).In this large, contemporary ICCU cohort, elevated IPF was independently associated with in-hospital mortality, as well as adverse outcomes. Although not a standalone discriminator, IPF is a readily available, low-cost biomarker that may enhance early mortality risk stratification when integrated with established clinical variables, supporting further evaluation in multimodal and machine learning-based prediction frameworks.

未成熟血小板分数作为心血管重症监护病房不良结局的独立标志。
血小板活化和血小板生成是急性心血管疾病病理生理学的核心,但在异质性心血管重症监护病房(ICCU)人群中,未成熟血小板分数(IPF)的预后作用仍未完全确定。我们进行了一项单中心观察性研究,对6,725名连续入icu的患者进行了IPF测量。主要终点为医院内全因死亡率,采用多变量logistic回归,并通过受试者工作特征分析进行区分。中位年龄为70岁;31.8%为女性。增加IPF四分位数显示死亡率(2.1 - 3.7%,p趋势= 0.003)、急性肾衰竭(ARF) (2.4 - 5.1%, p p = 0.002)和院内心源性休克(2.7 - 4.7%,p = 0.008)逐步上升;心源性休克的回归分析仅限于非休克入院的事件病例(n = 5778)。多变量调整后,IPF每增加1个自然对数单位(~ 1.7倍原始IPF)仍然与死亡率(OR 1.55, 95% CI: 1.10-2.19)、ARF (OR 1.75, 1.37-2.25)、恶性心律不齐(OR 2.07, 1.44-2.98)和心源性休克(OR 1.51, 1.16-1.96)独立相关。单独使用IPF的差异不大(AUC为0.57-0.59),但将其纳入多变量模型可改善性能(死亡率AUC为0.78)。再分类分析显示了超过基线的增量值(分类净再分类改善[NRI] +6.9至+12.1%;连续NRI 0.14-0.28)。在这个大型的当代重症监护室队列中,IPF升高与住院死亡率和不良结局独立相关。虽然IPF不是一个独立的鉴别器,但它是一种现成的低成本生物标志物,当与已建立的临床变量相结合时,可以增强早期死亡风险分层,支持在多模式和基于机器学习的预测框架中进行进一步评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Thrombosis and haemostasis
Thrombosis and haemostasis 医学-外周血管病
CiteScore
11.90
自引率
9.00%
发文量
140
审稿时长
1 months
期刊介绍: Thrombosis and Haemostasis publishes reports on basic, translational and clinical research dedicated to novel results and highest quality in any area of thrombosis and haemostasis, vascular biology and medicine, inflammation and infection, platelet and leukocyte biology, from genetic, molecular & cellular studies, diagnostic, therapeutic & preventative studies to high-level translational and clinical research. The journal provides position and guideline papers, state-of-the-art papers, expert analysis and commentaries, and dedicated theme issues covering recent developments and key topics in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书